Ligand Pharmaceuticals Incorporated LGND
301.52
2.48
0.83%
as of 25 Sep
- Market cap
- $6.1B
- P/E
- 30.1×
Follow LGND
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
5.42% | 13.47% | 17.13% | 21.96% | |
| 4.00% | 9.95% | 12.60% | 12.58% | ||
ROIC |
1.52% | 3.62% | 9.06% | 8.19% | |
Return on Tangible Assets |
6.68% | 15.66% | 18.62% | 13.98% | |
Average Days of Receivables |
84.40 | 83.12 | 72.87 | 87.84 | |
Free Cash Flow per Share |
0.62 | 3.15 | 6.77 | 7.15 | |
Free Cash Flow |
12.13 | 60.91 | 134.59 | 143.37 | |
Capital Expenditures |
(19.79) | 11.56 | 11.09 | 11.65 | |
Piotroski F-Score |
5.00 | 6.00 | 6.00 | 5.00 | |
| Other line items | |||||
Cash ROIC |
1.54% | 2.22% | 5.52% | 3.80% | |
Accounts Receivable Turnover |
5.01 | 5.18 | 5.62 | 4.75 | |
Accounts Payable Turnover |
3.44 | 3.44 | 2.44 | 1.48 | |
Inventory Turnover |
1.01 | 1.25 | 0.93 | 1.03 | |
Average Days of Payables |
93.29 | 81.23 | 148.10 | 258.50 | |
Days of Inventory on Hand |
301.76 | 228.95 | 373.24 | 282.08 | |
Tax Rate |
(0.23) | (0.22) | (0.17) | (0.17) | |
Research and Development Expense of Revenue |
32.68% | 30.28% | 12.11% | 14.23% | |
Selling, General and Administrative Expense of Revenue |
37.03% | 34.48% | 34.42% | 35.60% | |
Share Based Compensation of Revenue |
15.96% | 17.48% | 18.07% | 18.33% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.66 | 0.40 | 0.80 | 0.67 | |
Depreciation/Fixed assets |
9.09 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.63) | 0.38 | 0.38 | 0.40 | |
Revenue per Share |
12.83 | 13.86 | 13.80 | 14.48 | |
Operating CF per Share |
1.63 | 2.55 | 6.21 | 6.57 | |
Capex per Share |
(1.01) | 0.60 | 0.56 | 0.58 | |
Capex to Sales |
0.08 | (0.04) | (0.04) | (0.04) | |
Net Profit Margin |
19.34% | 46.42% | 55.95% | 67.88% |
Columns are period end dates